- CDC
- Heart Failure
- Cardiovascular Clinical Consult
- Adult Immunization
- Hepatic Disease
- Rare Disorders
- Pediatric Immunization
- Implementing The Topcon Ocular Telehealth Platform
- Weight Management
- Screening
- Monkeypox
- Guidelines
- Men's Health
- Psychiatry
- Allergy
- Nutrition
- Women's Health
- Cardiology
- Substance Use
- Pediatrics
- Kidney Disease
- Genetics
- Complimentary & Alternative Medicine
- Dermatology
- Endocrinology
- Oral Medicine
- Otorhinolaryngologic Diseases
- Pain
- Gastrointestinal Disorders
- Geriatrics
- Infection
- Musculoskeletal Disorders
- Obesity
- Rheumatology
- Technology
- Cancer
- Nephrology
- Anemia
- Neurology
- Pulmonology
Study Shows Migraineurs With Comorbid Mood Disorders Responded Well to Treatment
Patients with migraine accompanied by depression or anxiety disorders had greater improvements in headache-related disability than those without a psychiatric disorder, according to results of the Treatment of Severe Migraine trial.
Patients with migraine accompanied by depression or anxiety disorders had greater improvements in headache-related disability than those without a psychiatric disorder, according to results of the Treatment of Severe Migraine trial.1 Before this study, it was commonly assumed that patients with migraine and a psychiatric comorbidity do not fare as well during treatment, said Elizabeth Seng, MS, a graduate student at Ohio University in Athens, who presented the results at the International Headache Congress in Philadelphia. “Physicians should be encouraged by this new information: there is hope for their patients who present with psychiatric comorbidity,” said Seng in an interview with Consultant. “Even though their migraines are more severe and disabling initially, they respond even better to treatment than individuals without psychiatric comorbidity.”
In this study, 232 patients with severe migraine were treated with optimal acute medication for 1 month. After this period of treatment, patients were randomized into one of the following groups: placebo, propranolol, behavioral migraine management (BMM), and placebo, or BMM and propranolol. Patients received behavioral treatment as well as dose adjustment within a 4-month period and were later evaluated after 1 year.
Patients with migraine and either depression or anxiety had greater headache-related disability at baseline than patients with no psychiatric comorbidity. However, while results showed that all treatment groups had reduced headache-related disability, patients with mood disorders had greater decreases in headache-related disability than the rest of the patient population. “I was very surprised that individuals suffering from depression and anxiety, even though they started off with greater headache-related disability, caught up with the other individuals by the end of the study,” said Seng. “The groups were indistinguishable.”
The patients with psychiatric comorbidity may have showed greater improvement in headache-related disability because they had more room to improve, said Seng. “It is important for health care providers who treat migraine to know how initial psychiatric comorbidity can impact their treatment decisions and patient outcomes,” she said. “This can be a more difficult patient population to work with, but the benefits for the patients are substantial.”
References:
Reference
1. Seng EK, Holroyd KA, Cottrell CK, Drew JB. The presence of psychiatric comorbidity does not portend poorer treatment outcome. Presented at: the International Headache Conference; September 9-13, 2009; Philadelphia.
